BACKGROUND This study aimed at investigating antiepileptic drug (AED) prescription preferences in patients with brain tumor-related epilepsy (BTRE) among the European neuro-oncology community, the considerations that play a role when initiating AED treatment, the organization of care, and practices with regard to AED withdrawal. MATERIAL AND METHODS A digital survey containing 31 questions about prescription preferences of AEDs was set out among members of the European Association of Neuro-Oncology (EANO). RESULTS A total of 198 respondents treating patients with BTRE participated of whom 179 completed the entire survey. Levetiracetam was the first choice in patients with BTRE for almost all respondents (90% [162/181]). Levetiracetam was considered the most effective AED in reducing seizure frequency (72% [131/181]) and having the least adverse effects (48% [87/181]). Common alternatives for levetiracetam as equivalent first choice included lacosamide (33% [59/181]), lamotrigine (22% [40/181]), and valproic acid (21% [38/181]). Most crucial factors to choose a specific AED were potential adverse effects (82% [148/181]) and interactions with other antitumor treatments (76% [137/181]). In the majority of patients neuro-oncologists were involved in the treatment of seizures (73% [132/181])). Other relevant findings were that a minority of respondents ever prescribe AEDs in brain tumor patients without epilepsy solely as prophylaxis (29% [53/181]), but a majority routinely consider complete AED withdrawal in seizure free BTRE patients after antitumor treatment (79% [141/179]). CONCLUSION Our results show that among European professionals treating patients with BTRE levetiracetam is considered the first choice AED, with the presumed highest efficacy and least adverse effects.

中文翻译：

---

P14.49 脑肿瘤患者抗癫痫药物的处方偏好：一项国际调查

背景 本研究旨在调查欧洲神经肿瘤学界脑肿瘤相关性癫痫 (BTRE) 患者的抗癫痫药物 (AED) 处方偏好、开始 AED 治疗时的考虑因素、护理组织和实践关于 AED 撤出。材料和方法 在欧洲神经肿瘤学协会 (EANO) 的成员中进行了一项包含 31 个关于 AED 处方偏好的问题的数字调查。结果 共有 198 名治疗 BTRE 患者的受访者参与其中，其中 179 人完成了整个调查。几乎所有受访者（90% [162/181]）都将左乙拉西坦作为 BTRE 患者的首选。左乙拉西坦被认为是降低癫痫发作频率 (72% [131/181]) 和副作用最小 (48% [87/181]) 的最有效 AED。左乙拉西坦作为等效首选的常见替代品包括拉考沙胺 (33% [59/181])、拉莫三嗪 (22% [40/181]) 和丙戊酸 (21% [38/181])。选择特定 AED 的最关键因素是潜在的不良反应 (82% [148/181]) 和与其他抗肿瘤治疗的相互作用 (76% [137/181])。在大多数患者中，神经肿瘤学家参与了癫痫发作的治疗 (73% [132/181]))。其他相关发现是，少数受访者曾在没有癫痫的脑肿瘤患者中开过 AEDs 仅作为预防措施 (29% [53/181])，但大多数人通常会考虑在抗肿瘤治疗后无癫痫发作的 BTRE 患者中完全停用 AED (79% [141/179])。结论 我们的研究结果表明，在欧洲专业人员中，使用 BTRE 左乙拉西坦治疗患者被认为是首选 AED，据推测疗效最高且副作用最小。